| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10b81289cb0a3a34c6fcd4e4728ed5eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 |
| filingDate |
2017-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_775588d85dac6b647feb0b7d1a101cb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e35229b1c886d439d399b411a83419e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d617bcd6efc2dcf6a310082eb0cba6d |
| publicationDate |
2020-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3731934-A1 |
| titleOfInvention |
Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases |
| abstract |
The present disclosure is directed to IgE EMPD peptide immunogen constructs and formulations thereof for the treatment of IgE-mediated allergic diseases. The IgE EMPD peptide immunogen constructs have a B cell epitope peptide of more than 20 amino acids, preferably cyclic, linked through an optional spacer to heterologous T helper cell (Th) epitopes derived from pathogen proteins. These peptide immunogen constructs and formulations thereof can stimulate the generation of highly specific antibodies in vaccinated hosts that are directed against the IgE EMPD peptide and are crossreactive with membrane-bound IgE on B lymphocytes committed to IgE secretion. The antibodies induced by the peptide immunogen constructs and formulations thereof in vaccinated hosts can induce apoptosis of IgE-expressing B cells and mediate Antibody Dependent Cellular Cytototoxity (ADCC), resulting in reduction of antigen-specific IgE and total IgE levels in vaccinated hosts to effectively treat IgE-mediated allergic pathology. |
| priorityDate |
2017-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |